New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2

Business Wire India

New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective…and replicable means to deactivate SARS-CoV-2…to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains…” The Virucidal studies were independently funded.


“The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said Dr. Gustavo Ferrer, who is leading the research team.


State of scientific research:


Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19. Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19).


Xlear’s components are antiviral—they block viral adhesion in the nose. See, for example, This Univ. of Tennessee study on SARS-CoV-2 concluded: “antiviral nasal sprays…contribute reduce…viral load…slowing down disease progression…and transmission…”


Peer-reviewed case studies indicate Xlear helps in treating COVID-19: First-look trial at Larkin Community Hospital (Miami), determined: “symptomatic, COVID-19 patients, treated with [Xlear], as an adjunct to…[standard care],” showed “rapid clinical improvement and shorten[ed] time” to negative COVID-19 PCR tests.


Xlear has been used for over 20 years by millions of people worldwide without a single significant adverse incident report.


“Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2). This combination of antiviral and virucidal capabilities is an important one-two punch in fighting the virus,” said Nathan Jones, CEO of Xlear. “With the pandemic raging worldwide, we must use every tool we can to fight it. Failing that needlessly risks millions of lives. Weighing our 20-year safety record, against the risks of this deadly virus, it’s clear Xlear needs to be in widespread use,” Jones concluded.


Full study:


More information on Xlear:


About Dr. Gustavo Ferrer


Dr. Ferrer, MD FCCP, is an Associate Professor of Medicine and Founder of the Cleveland Clinic Florida Interstitial Lung Disease Clinic and the Aventura Hospital Pulmonary and Critical Care fellowship. He currently serves as President of Intensive Care Experts/Aventura Pulmonary Institute and previously served as United Nations University Director of Respiratory Research, Venezuela.